markets is the sole category represented across all 1 tracked stories. Evolus is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Rui Avelar
markets is the sole category represented across all 1 tracked stories. Evolus is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6.4. Rui Avelar appears in 1 tracked Finance story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 105 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Rui Avelar. Shared-story counts are live from our verified record — not editorial picks.
Evolus Chief Medical Officer Rui Avelar sold 29,996 shares of EOLS stock on March 19, 2026, following a period of significant price appreciation. The transaction occurs as the aesthetics company raises its long-term revenue targets and reports stabilizing trends in the neurotoxin market.